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174 L. Jacquet et al. / Stem Cell Research 16 (2016) 173–176We generated KCL040 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation
potential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping using array comparative genomic hybridiza-
tion aCGH identiﬁed reduced copy number at 5q13.2 (69,705,561–
70,388,844). The imbalance was not called by software. Whole-
genome single nucleotide polymorphism (SNP) array analysis detected
CN-LOH at 2q11.1–11.2 (94,871,756–98,412,364), gain at 12p11.21
(31,116,366–31,248,444), loss at 16p11.2 (32,491,547–33,993,220)
(Canham et al., 2015).
This CN-LOH at 2q11.1–11.2 contains multiple genes: TEKT4, MAL,
MRPS5, ZNF514, ZNF2, PROM2, KCNIP3, FAHD2A, TRIM43, ANKRD36C,
GPAT2, ADRA2B, ASTL, DUSP2, STARD7, TMEM127, CIAO1, SNRNP200,
ITPRIPL1, NCAPH, NEURL3, ARID5A, KANSL3, FER1L5, LMAN2L, CNNM4,
CNNM3, ANKRD23, ANKRD39, SEMA4C, FAM178B, FAHD2B, ANKRD36,
ANKRD36B, COX5B, ACTR1B, ZAP70, TMEM131, VWA3B, and CNGA3.Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell coGenetic size of this interstitial CN-LOH is relatively small and the double
recombination event required to this to happenwould be difﬁcult to ex-
plain (Kryh et al., 2011;O'Keefe et al., 2010). Therefore, it is unlikely that
is acquired (Canham et al., 2015).
The gain on chromosome 12p11.21 was also found in KCL033. The
region contains no genes and it has been also reported in at least 14 sub-
missions at Database of Genomic Variants (DGV; http://dgv.tcag.ca),
which has collected structural variations in more than 14,000 healthy
individuals from worldwide population (Macdonald et al., 2014). Esti-
mated frequency in the human population is 4.70% (Canham et al.,
2015).
The loss at 16p11.2 contains three related genes TP53TG3, TP53TG3C,
and TP53TG3B and it was reported previously in healthy population
(Shaikh et al., 2009; de Smith et al., 2007). Estimated frequency in the
human population is 5.14% (Canham et al., 2015).
The KCL040 line was negative for Human Immunodeﬁciency Virus 1
(HIV1), Hepatitis B (HepB, HCB), C Virus (HepC, HCV), Cytomegalovirus
(CMV) and Epstein–Barr Virus (EBV) by PCR. Mycoplasma was also not
detected.
We also generated research grade of KCL040 line that is adapted to
feeder-free conditions.
Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.8) were created on Mar. 11, 2010.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 8 — R.1 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Sep. 03, 2010. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 8 — R.2. HFEA
Code of Practice Edition 8 — R.1 was in effect: Oct. 01 2009–Apr. 06,
2010, whereas 8 — R.2 was in effect: Apr. 07, 2010–Apr. 06, 2011.4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
lonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
175L. Jacquet et al. / Stem Cell Research 16 (2016) 173–176Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICM plated on mitotically inactivated HFF was cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC
colonies were expanded and cryopreserved at the third passage.
Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
Pluripotency
Pluripotency in vitro was assessed using two different techniques:
enzymatic activity assay [alkaline phosphatase (AP) assay] and immu-
nostaining as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephenson
et al., 2012). Targeted differentiation in cardiomyocytes followed the
protocols described earlier (Jacquet et al., 2015; Laﬂamme et al., 2007).
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA ex-
traction robot according to themanufacturer's instructions. Ampliﬁcation
of polymorphic microsatellite markers was carried out as described
(Ilic et al., 2012). Allele sizes were recorded to give a unique ﬁngerprint
of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in details (Canham et al.,
2015).
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS)
Pathology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).
Special pathology
The Doctors Laboratory London (UK) tested the line for HIV1, HepB,
HepC, CMV and EBV by PCR.
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